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The Sentry inferior vena cava (IVC) filter is designed to provide temporary protection against pulmonary embolism (PE) during
transient high-risk periods and then to bioconvert after 60 days after implantation. At the time of bioconversion, the device’s nitinol
arms retract from the filtering position into the caval wall. Subsequently, the stable stent-like nitinol frame is endothelialized. The
Sentry bioconvertible IVC filter has been evaluated in a multicenter investigational-device-exemption pivotal trial (NCT01975090)
of 129 patients with documented deep vein thrombosis (DVT) or PE, or at temporary risk of developing DVT or PE, and with
contraindications to anticoagulation. Successful filter conversion was observed in 95.7% of patients at 6 months (110/115) and 96.4%
at 12 months (106/110). Through 12 months, there were no cases of symptomatic PE. The rationale for development of the Sentry
bioconvertible device includes the following considerations: (1) the period of highest risk of PE for the vast majority of patients
occurs within the first 60 days after an index event, with most of the PEs occurring in the first 30 days; (2) the design of retrievable
IVC filters to support their removal after a transitory high-PE-risk period has, in practice, been associated with insecure filter
dynamics and time-dependent complications including tilting, fracture, embolization, migration, and IVC perforation; (3) most
retrievable IVC filters are placed for temporary protection, but for a variety of reasons they are not removed in anymore than half of
implanted patients, and when removal is attempted, the procedure is not always successful even with advanced techniques; and (4)
analysis ofMedicare hospital data suggests that payment for the retrieval procedure does not routinely compensate for expense.The
Sentry device is not intended for removal after bioconversion. In initial clinical use, complications have been limited. Long-term
results for the Sentry bioconvertible IVC filter are anticipated soon.
1. Introduction
Treatment with anticoagulant agents is the established pri-
mary treatment for venous thromboembolic (VTE) disease.
For many patients, however, anticoagulation is contraindi-
cated or not effective, or it has to be discontinued during
periods of high risk for pulmonary embolism (PE). In these
situations, inferior vena cava (IVC) filters are recommended
in accordance with careful selection criteria developed by
various societies and expert panels [1, 2]. The purpose of
IVC filter placement is temporary or permanent mechanical
protection against PE, which is a major cause of morbidity
and mortality. Several systematic reviews of the literature
have shown that IVC filters are effective at providing such
mechanical protection [3–5].
Permanent IVC filters became available beginning in
the 1970s [6]. In response to adverse events (in particular
IVC thrombosis) and to concerns about long-term durability
and safety, retrievable IVC filters were developed in the
early 2000s [6]. More than a dozen retrievable IVC filters
have become commercially available in the United States
[7]. Retrievable IVC filters were approved by the US Food
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and Drug Administration (FDA) for permanent as well as
transient uses, but there was an expectation that the majority
of the filters would be retrieved, thus providing the benefit of
short-termmechanical caval filtrationwhile avoiding compli-
cations associated with permanent placement. Accordingly,
with the design priority of facilitating retrieval by limiting
endothelialization, their caval mounting can be relatively less
secure than that of permanent filters [6, 8]. The long-term
safety and efficacy of retrievable IVC filters as a class have not
been established [2].
While retrievable IVC filters have been designed with
awareness that — for good clinical reason or due to patients
being lost to follow-up — some will not be removed, nev-
ertheless in practice an unanticipated proportion of these
devices have been allowed to remain in place after the need
for temporary PE prophylaxis has passed. Less than half of
retrievable IVC filers are removed, and, in some studies,
retrieval rates have been as low as 8.5% [3, 9, 10]. A number
of studies and case reports have been published describing
time-dependent complications — such as tilting, fracture,
embolization, migration, or IVC perforation — associated
with retrievable IVC filters that remain indwelling [7]. Begin-
ning in 2010, the FDA has issued safety communications
about retrievable IVC filters [11]. In 2016, systematic follow-
up of patients with retrievable IVC filters at 3 months became
a Medicare quality metric [12].
By requiring a follow-up procedure for device removal,
retrievable IVC filters were designed to offset the risk of
adverse events associated with permanent mechanical caval
filtration such as late IVC thrombosis and filter migration. To
achieve that same end but avoid the necessity of a secondary
removal procedure, the Sentry IVC filter (BTG Vascular,
Bothell, WA) was designed to provide protection during the
high-PE-risk period (up to 60 days) and then bioconvert
from a filtering to a nonfiltering configuration (Figure 1).The
means of the conversion for the Sentry device is hydrolytic
biodegradation of a filament that holds together the six pairs
of arms that form the filter cone in the central portion of the
caval lumen. This filament is composed of poly-p-dioxanone
(PPDO), a hydrolyzing synthetic polymer that has been
widely used in biodegradable devices such as sutures [13].
After the PPDO filament biodegrades, the arms are released
and retract to the caval wall to become endothelialized along
with the stable stent-like device frame, reducing the risk
of filter migration or embolization and maintaining vessel
patency.The Sentry’s bioconversionmechanism thus obviates
the need for a separate secondary removal procedure as with
retrievable filters.
In this article, we discuss the clinical rationale for the
development of the Sentry bioconvertible IVC filter. We dis-
cuss considerations that informed the Sentry development:
(1) evidence that the period of highest risk of PE for the vast
majority of patients occurs within the first 60 days after an
index event, with most of the PEs occurring in the first 30
days; (2) evidence that retrievable IVC filters, which have
been a focus of safety communications from the FDA [11,
14], are associated with time-dependent complications, many
arising due to the design features of the devices and because
they are not routinely removed as intended; (3) evidence that
Figure 1: The Sentry bioconvertible IVC filter in filtering (above)
and bioconverted (below) configurations, with corresponding axial
views on the right.
when removal of retrievable IVC filters is actually attempted,
the procedures are frequently complex — with a failure rate
of approximately 10% [9] — requiring advanced techniques
such as the use of forceps, lead extraction devices, or lasers;
and (4) evidence— based on an analysis of Medicare hospital
data on cases of IVC filter removal— suggesting that the need
for complex filter retrievals presents an economic burden,
with reimbursement for the procedure not routinely compen-
sating for expense. We conclude the article by describing the
clinical development program of the Sentry bioconvertible
IVC filter and studies of the device to date.
2. Clinical Rationale for the Sentry
Bioconvertible IVC Filter
2.1. The Timing of PE after an Index Event. Risk factors for
PE include a history of deep vein thrombosis (DVT); recent
surgical procedures; hospitalization for cancer and chronic
conditions; prolonged inactivity or immobility; traumatic
injury; obesity; and advanced age [15]. Contemporary data
from large-population studies support the premise that the
period of highest risk for PE in patients with temporary
contraindications to anticoagulants occurs early, with the
clear majority of PEs diagnosed within 30 days of an index
event (hospitalization, traumatic injury, surgery). Table 1
summarizes the findings regarding the incidence and time
course of PE in trauma patients, and Table 2 summarizes
data on the postoperative incidence and time course of PE
in surgical patients.
In a retrospective chart review of 25,658 trauma patients
during the years 2001 to 2004 at four level 1 trauma centers,
Sing et al. [16] found an 0.6% incidence of PE, with a mean
time from injury to PE diagnosis of 7.9 ± 8.1 days and
with the latest event occurring at 43 days. In another large
retrospective chart review, by Coleman et al. [17], involving
data for 54,964 patients at three level 1 trauma centers from
2007 to 2013, the incidence of PE was 0.24%, with a median
time to PE diagnosis of 4 hospital days (interquartile range
[IQR] 1 to 8 days). Figure 2 diagrams the time course for the
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Figure 2: Time course to pulmonary embolism (PE) in patients at
level 1 trauma centers. AIS =Abbreviated Injury Scale. Adapted from
Brakenridge et al. [19] and Coleman et al. [17]
133 PEdiagnoses through 43 days in that study, along with the
timing of PE through 30 days in 48 patients with ≥1 long bone
fracture and 39with significant head injury between 2003 and
2007 in level 1 trauma center data reported by Brakenridge
et al. [19] Of the 108 PE diagnoses, overall in the study by
Brakenridge et al., 25% were within the first 72 hours, 50%
within the first 4 days, and 95% within 20 days [19]. In a
retrospective chart review by Batty et al. [20], the mean time
to PE for trauma patients was 12 days after injury, with a range
extending to 48 days.
In a study of 5607 patients who underwent major joint
surgery at a Norwegian hospital between 1989 and 2001,
Bjornara et al. [29] found that the median time to PE diag-
nosis was 17 days (range 1 to 173 days) following emergency
hip fracture surgery, 34 days (range 2 to 150 days) following
total hip replacement, and 12 days (range 2 to 150 days)
following total knee replacement (Figure 3). In a study of 115
PEpatients in a population of 111,773who underwent general,
orthopedic, and other surgical procedures from 1999 to 2004
at a North Carolina medical center, Hope et al. [22] found
that the mean time to PE diagnosis was 2.6 days for patients
<40 years of age, 11.2 days for those 40 to 60 years of age,
and 6.7 days for those >60 years. Of 1602 patients with VTE
following a variety of surgical procedures in the international
RIETE registry, as reported by Arcelus et al. [23], 787 were
diagnosed with PE— 19% during the first 7 days, 48% during
the first 15 days, and 77% during the first 30 days. Three
recent reports, based on the American College of Surgeons
National Surgical Quality Improvement Program database,
found a mean time to postoperative PE for thoracolumbar
surgery patients of 9.4 ± 7.3 days [24], a median time to PE
for nephrectomy patients of 6 days (IQR 3 to 13 days) [25],
and a median time to PE for lung cancer resection patients of
11 days (IQR 5 to 17 days) [26]. Recently among numerous
studies of postoperative PE in orthopedic surgery patients,
Parvizi et al. [31] found an incidence following total joint
arthroplasty of 1.07% (283/26,415), with a median time to
diagnosis of 2 days (range 1 to 87 days) — 81% within the first
3 days, 89% within the first week, and 94% within 2 weeks.
In adult femur fracture patients who underwent computed
tomography (CT)within 72 hours after admission at a Korean
medical center, Kim et al. [32] found a PE incidence of 2.2%
(28/453) —with the PE detected in 57.1% in the first 24 hours
after injury and in 89.3% in the first 48 hours.
2.2. Time-Dependent Complications of Retrievable IVC Filters.
Clinician and public concern about high rates of com-
plications associated with retrievable IVC filters followed
numerous reports in the literature and was amplified by the
issuing of a safety communication from the FDA in April
2010 [11]. The safety communication has been associated
with a decrease in the utilization of IVC filters [33]. Several
systematic reviews of retrievable IVC filters have assessed
overall and specific device-related complications. Table 3
shows reported rates for key filter-related complications from
three systematic reviews [3, 7, 9] and from two analyses
of adverse events that were voluntarily self-reported by
clinicians to the FDAManufacturer and User Facility Device
Experience (MAUDE) database [3, 34].
The April 2010 FDA safety communication stated that,
because of the number of reports of device-related adverse
events received since 2005, the FDA was concerned that
retrievable IVC filters, “intended for short-term placement,
are not always removed once a patient’s risk of PE has
subsided,” and that retrieval is important because “long-term
risks associated with IVC filters include but are not limited
to DVT, filter fracture, filter migration, filter embolization,
and IVC perforation” [11]. In May 2014, the FDA updated
the April 2010 safety communication, again urging physicians
to consider removing retrievable IVC filters as soon as PE
protection is no longer needed [14].
In the 2014 update, two FDA initiatives were highlighted.
The first was development of a quantitative decision analysis,
using data from the literature about IVC filters, to assess
whether a time point could be identified beyond which the
risk of keeping an IVC filter in place might outweigh the
benefits. This mathematical model, published by Morales et
al. in 2013 [35], suggested that if a patient’s transient risk
requiring mechanical protection against PE has passed, the
risk/benefit profile favors removal of the IVCfilter between 29
and 54 days after implantation. This analysis and supporting
data suggested that the vast majority of cases of PE occur well
within 60 days of an index event, affirming the selection of a
60-day biodegradation window for the filament holding the
filter-cone-forming arms of the Sentry IVC filter.
The second FDA initiative involved collection of data for
IVC devices currently marketed in the United States in order
to reassess their effectiveness and safety. Two options were
given to manufacturers for providing data: (1) postmarket
surveillance or (2) participation in the Predicting the Safety
and Effectiveness of Inferior Vena Cava Filters (PRESERVE)
trial (NCT02381509). Sponsored by the IVC Filter Study
Group Foundation, a joint collaboration between the Society
of Interventional Radiology (SIR) and the Society for Vascu-
lar Surgery, PRESERVE is a multicenter, prospective, open-
label, nonrandomized registry of commercially available
IVC filters from 6 manufacturers placed in patients for the
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Figure 3: Median days to pulmonary embolism (PE) in large surgery populations. IQR = Interquartile range. Data from Jordan et al. [25],
Thomas et al. [26], Parvizi et al. [31], and Bjornara et al. [29].
prevention of PE. Enrollment was begun in October 2015.
As of August 2018, according to the SIR Foundation, 4 of
the 6 originally included filters had reached their 300-patient
cap and had their enrollment closed. Data are expected from
PRESERVE in 2019.
In 2014, Andreoli et al. [34] compared retrievable and
permanent IVC filters in terms of adverse events reported to
MAUDE for the period of January 2009 through 2012. For
statistical purposes, the investigators estimated that 75% of
the filters present in the population during that time period
were retrievable IVC filters. Of the 1696 MAUDE adverse
events associated with 1057 IVC filters for that time period,
86.8% involved retrievable IVC filters, whereas only 13.2%
involved permanent IVCfilters (p<0.0001). For every specific
complication — including tilting, fracture, embolization,
migration, IVC perforation, and venous thromboembolism
— absolute numbers were significantly higher for retrievable
IVC filters than for permanent IVC filters.
In a 2011 systematic review of retrievable IVC filters,
Angel et al. [3] included an analysis of MAUDE data on
retrievable IVC filters, adding the insight that almost all
MAUDE events (93%) occurred after 30 days. The systematic
review identified 37 studies in the literature in which 6834
patients received retrievable IVC filters. The mean follow-
up of the studies was 9.9 months (range 2 to 25 months).
The rate of device-related complications associated with
retrievable IVC filters was low, the investigators stated, but
time-dependent, with few complications reported within
30 days of filter implantation. The mean retrieval rate was
“extremely low” 34% (range 12% to 45%).
In a 2018 systematic review of retrievable IVC filters
conducted by Jia et al. [9], the retrieval rate was found to
be similarly low at 34.9%, although 85% of the IVC filter
placements were intended to be temporary. This system-
atic review identified 103 studies in which 20,319 patients
received retrievable IVC filters. The investigators noted a
low incidence of complications but underscored that median
follow-up was only 140 days (range 18 to 3279 days) and
that complications increased with longer indwelling times.
Retrieval attempts failed for 13.7%of all implanted IVC filters.
In 2016, Deso et al. [7] analyzed complications according
to permanent or retrievable IVC filter brands and types.
Many different IVC filters and filter design types have been
approved by the FDA since 1980. The investigators identified
9 permanent IVC filter brands, of which 3 were no longer
manufactured in 2016, and they identified 14 retrievable
IVC filter brands, of which 7 were no longer manufactured
in 2016 [7]. The Deso et al. systematic review found 73
articles reporting IVC filter complications. For the retrievable
IVC filters identified in this analysis, the proportions with
reported rates >10% in selected complication categories are
included in Table 3. In this review — as in the Andreoli et al.
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Table 3: Selected complications of retrievable IVC filters reported in three systematic reviews and two analyses of the FDAMAUDEdatabase.
Complication Reports
Filter fracture
Structural failure of the filter leading to fragmentation
Reported in specific systematic reviews
(i) 0.5% (50/9509 patients) [9]
(ii) 6 of 14 articles reported fracture rates >10% [7]
Percentage of reported MAUDE complications
(i) 22.0% (2011) [3]
(ii) 23.9% (2014) [34]
Filter migration
Movement >2 cm above or below initial placement
Reported in specific systematic reviews
(i) 1.3% (35/2716 patients) [3]
(ii) 1.4% (160/11,679) [9]
(iii) 4 of 14 articles reported migration rates >10% [7]
Percentage of reported MAUDE complications
(i) 22.0% (2011) [3]
(ii) 12.1% (2014) [34]
Filter perforation
Penetration of a filter component >3 mm of vena cava wall
Reported in specific systematic reviews
(i) 5.4% (379/7001 patients) [9]
(ii) 5 of 14 articles reported perforation rates >20% [7]
Percentage of reported MAUDE complications
(i) 20% (2011) [3]
(ii) 15.4% (2014) [34]
Filter tilt
An angulation >15 degrees from the long axis of the vena cava
Reported in specific systematic reviews
(i) 7.7% (798/10,348) [9]
(ii) 5 of 14 articles reported tilting rates >10% [7]
Percentage of reported MAUDE complications
(i) 3.9% (2014) [34]
Deep vein thrombosis
Reported in specific systematic reviews
(i) 5.4% (69/1277 patients) [3]
(ii) 7.1% (362/5092 patients) [9]
IVC thrombosis/stenosis
Reported in specific systematic reviews
(i) 2.8% (116/4078 patients), 37 studies [3]
(ii) 3.9% (345/8788 patients), 103 studies [9]
Percentage of reported MAUDE complications
(i) 2.3% (2014) [34]
Sources: Systematic reviews:Angel et al. (2010) [3], Deso et al. (2016) [7], Jia et al. (2018) [9];MAUDE analyses:Andreoli et al. (2014) [34], Angel et al. (2010) [3]
review of the MAUDE database [34] — the most commonly
reported complications varied among the brands of retriev-
able filters. The rate of filter fracture for the Bard Recovery
IVC retrievable filter (C.R. Bard Peripheral Vascular, Tempe,
AZ) was reported to be as high as 39.5%; for the Cordis
OptEase/TrapEase IVC filter (Miami Lakes, FL), the filter-
fracture rate was reported to be as high as 50%. Rates of
filter penetration for the Bard Recovery and the Cook Celect
(Bloomington, IN) retrievable IVC filters were reported to
exceed 90% [7].
Among the IVC filter brands included in the Deso
et al. analysis, the most common design type, used in
more than half the devices, was conical. When such a
design is involved, the investigators advised, routine assess-
ment for IVC filter perforation should be performed. With
such devices, the endothelialization-limiting (and intended
retrieval-facilitating) point contact on the part of the filter
legs can lead to penetration of the caval wall and to instability
and tilting. For device designs with cylindrical frame ele-
ments, the investigators advised assessment for IVCocclusion
[7]. In the case of the OptEase retrievable device with filter
elements at each end of a box-like cylindrical frame, the high
metal contentwithin the lumen and associated abnormal flow
characteristics can induce occlusion [36].
Other studies have specifically examined complications
with retrievable IVC filters, sometimes focusing on institu-
tional experiences [10, 37], specific IVC filter brands [38–
40], or difficulties that complications present in relation to
attempts at IVC filter retrieval [41–44]. A notable analy-
sis was another systematic review by Jia et al. [45] that
examined the effects of caval penetration by IVC filters. A
total of 88 clinical studies and 112 case reports qualified
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for analysis, representing 9002 patients and 15 filter types.
The overall penetration rate was 19% of patients, and
almost one in five of those penetrations showed evidence of
organ/structure involvement. Among patients with penetra-
tion, 8% were symptomatic, 45% were asymptomatic, and
47% had unknown symptomatology. The most frequently
reported symptom was pain (77%), and major complications
were reported in 5% of patients, including 2 deaths. The
investigators stated that caval penetration by IVC filters
occurs frequently but is poorly recognized, although almost
one tenth of the penetrations caused symptoms.
In summary, the recognition that prompted the develop-
ment of retrievable IVC filters— that a device providing caval
mechanical filtration is increasingly likely to develop compli-
cations over time — has also held true for retrievable IVC
filters, which were specifically designed with modification to
the caval attachment sites so that they could be removed. To
date, there have been no randomized controlled trials directly
comparing permanent and retrievable IVC filters. Review of
the MAUDE database, for example, suggests that, after the
need formechanical PE prophylaxis has passed, complication
rates might indeed be higher with retrievable IVC filters than
with permanent IVC filters [34].
2.3. The Complexity of IVC Filter Retrieval. The 2010 FDA
safety communication stimulated efforts to improve upon the
low retrieval rates of IVC filters. Because lack of systematic
follow-up of patients receiving IVC filters was identified as
an important reason for the absence of attempts at retrieval,
several dedicated tracking programs were set up to improve
filter retrieval rates. After a filter registry was initiated in one
program, retrieval rates improved from 15.5% to 31.5% [46].
Another program, which sent automated letters to physicians
and made automated follow-up appointments, improved
retrieval rates from 8% to 52% [47]. A third program, which
focused on both physician education and patient tracking,
improved retrieval rates from 38.9% to 54%, while use of IVC
filters decreased by 18.7% [48]. Since 2012, in the Medicare
population, when a uniqueCommonProcedureTerminology
(CPT) code (37193)was introduced for IVCfilter retrieval, the
net annual filter retrieval rate increased from 6.9% in 2012 to
22.1% in 2016 [49].
The 2010 FDA safety communication raised clinician
awareness that retrievable IVC filters can in fact be chal-
lenging to remove. Significant filter tilt, an embedded filter,
a caval strut perforation, a filter fracture, or the presence of
thrombus within the filter — in addition to ordinary tissue
ingrowth and strut epithelialization — can make retrieval
problematic [50, 51]. Dinglassan et al. [52] examined prere-
trieval filter characteristics noted by CT that were associated
with complicated retrieval procedures, comparing 48 patients
with complicated retrievals versus 48 control patients with
uncomplicated retrievals. They found that mediolateral and
anteroposterior tilt angle, degree of perforation, and dwell
time were higher for the complicated retrieval group than
for the uncomplicated retrieval group (p <0.01). The odds
of complicated retrieval were increased by an embedded
tip appearance on CT (odds ratio [OR] 129, p <0.0001); a
tilt angle >15 degrees (OR 33, p <0.0001), a higher-grade
perforation (OR 10.7, p<0.001), and dwell time>180 days (OR
2.3, p <0.05).
Recent reviews have analyzed standard and advanced
techniques for achieving IVC filter retrieval, including such
methods as laser thermal and endobronchial forceps dissec-
tion [50, 53, 54]. Case reports have described open surgical
removal of IVCfilters, a last resort for patientswith symptoms
referable to filter strut penetration, such as chronic back and
abdominal pain, after failed endovascular attempts [55]. In a
retrospective analysis of filter retrieval over a 10-year period
in 217 patients, Al-Hakim et al. [56] found that the routine
standard technique of snaring the filter hook and sheathing
the filter was successful in 73.2% of patients, failing most
frequently because of significant filter tilt or an embedded
hook. For those patients for whom the routine technique
failed, advanced techniques had a success rate of 94.7%
but required significantly longer fluoroscopy time and had
a significantly higher complication rate (5.3% vs. 0.4%, p
<0.05).
2.4. The Cost of IVC Filter Retrieval. In order to analyze
Medicare claims associated with IVC filter retrieval, we
extracted cost and payment data from the 2016 Medicare
outpatient hospital standard analytical file for CPT code
37193, the code specific for IVC filter removal [57]. A
total of 6687 outpatient IVC filter retrieval procedures
were billed to Medicare in 2016; of these procedures, 1140
(17.0%) required the use of anesthesia. Medicare payments
were calculated from final claims for which Medicare was
the primary payer, payment was not denied, and there
were no other outlier payments. Costs were estimated by
applying the 2016 cost-to-charge ratio for each hospital, as
determined by the US Center for Medicare and Medicaid
Services, to the charges billed by each hospital for CPT
code 37193. As seen in Table 4, in 2016, Medicare payment
for outpatient IVC filter removal did not routinely appear
to cover hospital costs. The median payment was $1767.49
(interquartile range $1683.78–$1921.01), but the median cost
was $3129.57 (interquartile range $2457.04–$4167.18). Conse-
quently, median Medicare payment was only 56% of median
cost in 2016 for removal of IVCfilters, a difference of $1362.08,
and themedian interquartile range for paymentwas narrower
than the median interquartile range for cost. No doubt, part
of the shortfall in 2016 Medicare payments for the costs of
IVCfilter removalwas covered by copayments fromMedicare
patients, but such copayments do not generally exceed 20%
of the Medicare payment. The Sentry IVC filter, again, is not
designed to be retrieved after bioconversion and therefore
obviates the need for the retrieval procedure.
3. Sentry IVC Filter Description
and Performance
The Sentry IVC filter is made from a single piece of laser-
cut nitinol, which is formed into a stable self-centering
cylindrical frame with an integral filter cone consisting of
6 pairs of arms held together in the center of the IVC
lumen by means of the bioabsorbable PPDO filament. The
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Table 4: Cost and payment data extracted from the 2016 Medicare outpatient hospital standard analytical file for the common procedural
terminology code 37193 (IVC filter removal) [57].
Procedure No anesthesia With anesthesia Total
Cases 5547 1140 6687
Median cost (IQR) $3033.44($2385.49 – $3925.33)
$3865.22
($2909.70 – $5407.56)
$3129.57
($2457.04 – $4167.18)
Minimum cost $448.12 $846.91
Maximum cost $70,881.80 $37,540.94
Median payment (IQR) $1762.54($1682.49 – 1897.33)
$1795.42
($1687.45 – $2080.32)
$1767.49
($1683.78 – $1921.01)
Minimum payment $753.52 $809.18
Maximum payment $20,797.21 $10,959.56
IQR: interquartile range
cylindrical nitinol frame is designed to expand upon deploy-
ment to appose the caval wall (without point contact), such
that it concentrically and longitudinally optimizes flow and
distributes radial force in order to decrease device tilting,
migration, perforation, and fracture as endothelialization
and neointimal healing commence. Six fixation barbs (4
in the cranial direction and 2 in the caudal direction) are
located on the nitinol frame to keep the device securely
in place and minimize device migration. When the bioab-
sorbable filament hydrolyzes and releases the filter-cone-
forming arms after 60 days, they retract to the caval wall by
means of the nitinol shape memory to their nonfiltering set
position for endothelialization along with the stable stent-
like device frame (Figure 4). This design allows temporary
protection against PE followed bymaintenance of IVC lumen
patency.
The Sentry device is indicated for use in IVC with diam-
eters between 16 and 28 mm and has a maximum deployed
length of 57.7 mm. The filter comes preloaded in a loading
tool, which is attached to a custom introducer sheath for
deployment. It is suitable for a femoral or jugular approach.
The filter is advanced through the introducer sheath using a
pusher, which is supplied with the device. Once the device is
in the intended location, the pusher is held stationary and the
introducer sheath is retracted to execute deployment.
3.1. Animal Studies. The performance and stages of incorpo-
ration of the Sentry IVC filter were examined in an ovine
model. Sheep were used, as required by the FDA, because
their IVC sizes are closer to IVC sizes in humans than are
IVC sizes in pigs or dogs [58]. A total of 24 Sentry study
devices and 1 control retrievable IVC filter were implanted
in the infrarenal IVC of 25 sheep, with daily monitoring
and imaging and posttermination necropsy. The devices and
animals were treated and evaluated in two distinct cohorts:
(1) early-incorporation analysis cohort, with termination and
necropsy performed ≤98 days after implantation (n = 10
study devices) and (2) late-incorporation analysis cohort, for
assessment of device incorporation (cylindrical frame and
retracted filter arms), with termination and necropsy planned
for 180 ± 30 days after implantation (n = 14 study devices and
1 control device).
The results of the animal studies have been reported by
Gaines et al. [59]. In all 24 animals that received study devices,
deployment and positioning in the filtering configuration in
the center of the IVC lumen were successful, and pre- and
posttermination examinations confirmed that all filters had
bioconverted as intended, leaving the IVC lumens patent. For
the animals terminated at ≤98 days, imaging and necropsy
showed that the stabilizing stent part of the Sentry frame
was incorporated in the vessel wall, and the filter arms were
retracted. For the animals terminated at 180 ± 30 days,
imaging, necropsy, and histopathology confirmed that the
filter arms as well as frames were stably incorporated in
the vessel wall and that the IVC lumens were unobstructed
and patent. Figure 5 shows a representative section from
the histological analysis through the tips of the Sentry filter
arms, stained with hematoxylin and eosin, confirming the
integration of the filter arms into the wall of the IVC. The
high-power magnification of the section shows the residual
PPDO filter element surrounded by chronic inflammatory
cells adjacent to a fully incorporated tip of a filter arm.
Through 180 days, there were no filter-related complications.
3.2. Pivotal SENTRY Clinical Trial. The prospective, multi-
center, nonrandomized, single-arm SENTRY Clinical Trial
(NCT01975090) was conducted at 23 sites in the United States
(n = 20), Belgium (n = 2), and Chile (n = 1). Patients eligible
for inclusion were over 18 years of age and were determined
by their physicians to be at temporary (<60 days) risk of PE.
All patients had documented DVT or PE or were at high risk
of developing DVT or PE and had a contraindication to or
failure of anticoagulation. These indications for enrollment
were consistent with American College of Radiology (ACR)
and SIR practice and quality improvement guidelines [2,
61]. Patients were monitored by radiography, CT, and CT
venography in order to assess filtering configuration through
60 days, filter bioconversion, and incidence of PE and filter-
related complications through 12 months.
The one-year results of the SENTRY Clinical Trial have
been reported by Dake et al. [60]. In summary, 129 subjects
were enrolled, 87 with a therapeutic indication and 42 with
a prophylactic indication. Clinical success — defined as
successful filter deployment, freedom fromnew symptomatic
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Figure 4: Computed tomography imaging of the Sentry bioconvertible IVC filter for a single patient. (a) Coronal image acquired as part of
helical dataset 1 month after filter placement, showing the Sentry device in filtering configuration. (b) Coronal image at 6-month follow-up
showing the device in bioconverted configuration. ((c), (d), (e)) Axial views of the bioconverted device at 6-month follow-up, with the images
keyed to the coronal view in (b). Reprinted with permission from Dake et al. [60]
PE through 60 days before filter bioconversion, and 6-month
freedom from filter-related complications — was achieved in
111 of 114 evaluable patients (97.4%, 95%CI 92.5%-99.1%), and
device deployment was successful in all patients. The rate of
freedom from new symptomatic PE was 100% through 60
days (n = 129, 95% CI 97.1%-100.0%) and 100% (n = 111, 95%
CI 97.1%-100.0%) through 12 months. Through 60 days, the
rate of new or worsening DVT was 7.8% (none confirmed to
be device related), similar to recent findings for retrievable
filters. Filter bioconversion was successful for 95.7% (110/115)
at 6 months and 96.4% (106/110) at 12 months. Two patients
(1.6%) developed symptomatic caval thrombosis during the
first month; neither experienced recurrence after successful
treatment with thrombectomy and thrombolysis. There was
no filter tilting, migration, embolization, fracture, or caval
perforation, and no filter-related death through 12 months.
Overall, through 1 year, the Sentry IVC filter provided safe
and effective mechanical protection against PE.
The reasons for the nonconversion of the Sentry IVC
filter in 4 patients as of 12-month follow-up cannot be
accurately determined. In preclinical studies, the presence
of fibrin strands was occasionally noted at the ends of
filter arm, and such a circumstance could delay or prevent
separation of the arms [59]. In context, however, the 96.4%
rate of bioconversion far surpasses reported retrieval rates
for IVC filters [3, 9, 10]. In a relatively small percentage of
patients, then, the risks associated with nonconversion may
be seen as similar to the risks associated with a permanent
or unretrieved IVC filter. In the 12-month follow-up of
the SENTRY Clinical Trial, no patient experienced clinical
sequelae related to device nonconversion, and in particular
no PE or caval thrombosis.
Regarding the situation in which the Sentry IVC filter
has captured a large thrombus prior to bioconversion, the
protocol-mandated 1-month CT venography in the SENTRY
Clinical Trial revealed the presence of thrombus in 15.8% of
patients (18/114), and this thrombus was symptomatic in 2
patients. None of these patients experienced a PE through
12 months. At 2 months, data from a CT venogram was
available for 10 of the 18 patients: in 3, the clot had completely
resolved; in 5, the size of the clot was reduced; and in one, the
clot was slightly longer (increase of <4 mm) while its width
was decreased. In one patient imaging was not of sufficient
quality to judge any change in size, although the continuing
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Figure 5: Histological images of the integration of the Sentry
filter arms into the wall of the inferior vena cava. Above: section
cut through the tips of the filter arms stained with hematoxylin
and eosin. Below (dark red box in image above): residual filament
material surrounding chronic inflammatory cells adjacent to the
fully incorporated tip of a filter arm. Reprinted with permission
from Gaines et al. [59]
presence of thrombus was confirmed. The Sentry IVC filter
was designed not to tilt, and any trapped thrombus is thus
retained in the center of the vessel where the body’s own
lysis capabilities may be maximized, reducing the size of the
trapped clot to subclinical levels. It is unlikely that the trapped
clot is “free floating,” as it tends to become adherent to the
filter elements.
Longer-term follow-up of the SENTRY Clinical Trial is
underway, and 24-month follow-up will include CT venog-
raphy, further reporting of complications, and confirmation
of IVC patency.
4. Summary
Risk factors for PE include a history of deep vein thrombosis
(DVT); recent surgical procedures; hospitalization for cancer
and chronic conditions; prolonged inactivity or immobility;
traumatic injury; obesity; and advanced age [15]. The Sentry
bioconvertible inferior vena cava (IVC) filter provides tem-
porary protection against PE in patients during such high-
risk periods. When the device’s central filament hydrolyzes
after a protection period of 60 days, the filtering arms are
designed to retract into the caval wall by means of nitinol
shape memory and the stable stent-like device frame is
endothelialized, maintaining lumen patency. Complications
with the Sentry are limited, and, as the device is not intended
for removal, no secondary procedure is required. The Sentry
bioconvertible IVC filter has been evaluated in a multicenter
investigational-device-exemption pivotal trial of 129 patients,
with successful filter conversion occurring for 95.7% of
patients at 6 months (110/115) and 96.4% of patients at 12
months (106/110). Through 12 months in the trial follow-up,
there have been no cases of PE.
Considerations that figured in the clinical rationale for
development of the Sentry device included (1) contemporary
data on PE timing from large-population studies supporting
the premise that the period of highest risk for PE in patients
with temporary contraindications to anticoagulants occurs
early, with the clear majority of PEs diagnosed within 30
days of an index event (hospitalization, traumatic injury,
surgery), well within the Sentry’s targeted 60-day window
for automatic device conversion; (2) evidence that retrievable
IVC filters are associated with time-dependent complica-
tions, many arising due to the design features of the devices
and because they are not routinely removed as intended;
(3) evidence that when removal of retrievable IVC filters is
actually attempted, the procedures are frequently complex
and require advanced techniques; and (4) evidence — based
on an analysis of Medicare hospital data — suggesting that
the need for complex filter retrievals presents an economic
burden, with reimbursement for the procedure not routinely
compensating for expense.
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